| MeSH term | MeSH ID | Detail |
|---|---|---|
| Body Weight | D001835 | 333 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Edema | D004487 | 152 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
| Inflammation | D007249 | 119 associated lipids |
| Hypertension | D006973 | 115 associated lipids |
| Glioma | D005910 | 112 associated lipids |
| Weight Gain | D015430 | 101 associated lipids |
| Insulin Resistance | D007333 | 99 associated lipids |
| Diabetes Mellitus | D003920 | 90 associated lipids |
Anandamide
Anandamide is a lipid of Fatty Acyls (FA) class. Anandamide is associated with abnormalities such as Dehydration. The involved functions are known as Process, Phenomenon, Phosphorylation, Catabolic Process and Gene Expression. Anandamide often locates in Nuchal region, Microglial and Hepatic. The associated genes with Anandamide are SGPL1 gene, SPTLC1 gene, RPSA gene, KDSR gene and SMPD1 gene. The related lipids are Sphingolipids, Lipopolysaccharides, Lysophospholipids, LYSO-PC and lysophosphatidylethanolamine.
Cross Reference
Introduction
To understand associated biological information of Anandamide, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Anandamide?
Anandamide is suspected in Dehydration and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Anandamide
PubChem Associated disorders and diseases
What pathways are associated with Anandamide
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Anandamide?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Anandamide?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Anandamide?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with Anandamide?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Anandamide?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with Anandamide
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Starowicz K et al. | Biochemistry and pharmacology of endovanilloids. | 2007 | Pharmacol. Ther. | pmid:17349697 |
| Burstein SH | The cannabinoid acids: nonpsychoactive derivatives with therapeutic potential. | 1999 | Pharmacol. Ther. | pmid:10341359 |
| Izzo AA and Sharkey KA | Cannabinoids and the gut: new developments and emerging concepts. | 2010 | Pharmacol. Ther. | pmid:20117132 |
| Woodward DF et al. | The pharmacology and therapeutic relevance of endocannabinoid derived cyclo-oxygenase (COX)-2 products. | 2008 | Pharmacol. Ther. | pmid:18700152 |
| Goutopoulos A and Makriyannis A | From cannabis to cannabinergics: new therapeutic opportunities. | 2002 | Pharmacol. Ther. | pmid:12182958 |
| Hansen HS et al. | Putative neuroprotective actions of N-acyl-ethanolamines. | 2002 | Pharmacol. Ther. | pmid:12182959 |
| Randall MD et al. | Cardiovascular effects of cannabinoids. | 2002 | Pharmacol. Ther. | pmid:12182966 |
| Snider NT et al. | Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications. | 2010 | Pharmacol. Rev. | pmid:20133390 |
| Blankman JL and Cravatt BF | Chemical probes of endocannabinoid metabolism. | 2013 | Pharmacol. Rev. | pmid:23512546 |
| Mulè F et al. | Evidence for a modulatory role of cannabinoids on the excitatory NANC neurotransmission in mouse colon. | 2007 | Pharmacol. Res. | pmid:17574859 |
| Khasabova IA et al. | JZL184 is anti-hyperalgesic in a murine model of cisplatin-induced peripheral neuropathy. | 2014 | Pharmacol. Res. | pmid:25304184 |
| Mulè F et al. | Involvement of CB1 and CB2 receptors in the modulation of cholinergic neurotransmission in mouse gastric preparations. | 2007 | Pharmacol. Res. | pmid:17656103 |
| Navarria A et al. | The dual blocker of FAAH/TRPV1 N-arachidonoylserotonin reverses the behavioral despair induced by stress in rats and modulates the HPA-axis. | 2014 | Pharmacol. Res. | pmid:24861565 |
| Kerr DM et al. | Pharmacological inhibition of fatty acid amide hydrolase attenuates social behavioural deficits in male rats prenatally exposed to valproic acid. | 2016 | Pharmacol. Res. | pmid:27592249 |
| Yousif MH and Oriowo MA | Inhibitory effects of cannabinoid receptor ligands on electrically-evoked responses in rat isolated tracheal ring segments. | 1999 | Pharmacol. Res. | pmid:10527656 |
| Spradley JM et al. | Inhibitors of monoacylglycerol lipase, fatty-acid amide hydrolase and endocannabinoid transport differentially suppress capsaicin-induced behavioral sensitization through peripheral endocannabinoid mechanisms. | 2010 | Pharmacol. Res. | pmid:20416378 |
| Guindon J et al. | Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment. | 2013 | Pharmacol. Res. | pmid:23127915 |
| De Petrocellis L et al. | N-palmitoyl-vanillamide (palvanil) is a non-pungent analogue of capsaicin with stronger desensitizing capability against the TRPV1 receptor and anti-hyperalgesic activity. | 2011 | Pharmacol. Res. | pmid:21215315 |
| Stefano GB et al. | 2-arachidonyl-glycerol stimulates nitric oxide release from human immune and vascular tissues and invertebrate immunocytes by cannabinoid receptor 1. | 2000 | Pharmacol. Res. | pmid:10987990 |
| Malek N et al. | The multiplicity of spinal AA-5-HT anti-nociceptive action in a rat model of neuropathic pain. | 2016 | Pharmacol. Res. | pmid:27326920 |
| Fowler CJ and Ghafouri N | Does the hydrolysis of 2-arachidonoylglycerol regulate its cellular uptake? | 2008 | Pharmacol. Res. | pmid:18675915 |
| Nicolussi S et al. | Guineensine is a novel inhibitor of endocannabinoid uptake showing cannabimimetic behavioral effects in BALB/c mice. | 2014 | Pharmacol. Res. | pmid:24412246 |
| Maione S et al. | Piperazinyl carbamate fatty acid amide hydrolase inhibitors and transient receptor potential channel modulators as "dual-target" analgesics. | 2013 | Pharmacol. Res. | pmid:23911581 |
| Khasabova IA et al. | Increasing 2-arachidonoyl glycerol signaling in the periphery attenuates mechanical hyperalgesia in a model of bone cancer pain. | 2011 | Pharmacol. Res. | pmid:21440630 |
| Baranowska-Kuczko M et al. | Endothelium-dependent mechanisms of the vasodilatory effect of the endocannabinoid, anandamide, in the rat pulmonary artery. | 2012 | Pharmacol. Res. | pmid:22627170 |
| Fowler CJ et al. | The endocannabinoid signaling system: pharmacological and therapeutic aspects. | 2005 | Pharmacol. Biochem. Behav. | pmid:15935456 |
| Smith FL et al. | Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. | 1998 | Pharmacol. Biochem. Behav. | pmid:9610941 |
| Wiley JL | Cannabis: discrimination of "internal bliss"? | 1999 | Pharmacol. Biochem. Behav. | pmid:10515300 |
| Romero J et al. | Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to delta 9-tetrahydrocannabinol. | 1995 | Pharmacol. Biochem. Behav. | pmid:7675852 |
| Wiley JL and Burston JJ | Chronic Delta9-tetrahydrocannabinol during adolescence increases sensitivity to subsequent cannabinoid effects in delayed nonmatch-to-position in rats. | 2010 | Pharmacol. Biochem. Behav. | pmid:19941884 |
| Herrera-SolÃs A et al. | Acute and subchronic administration of anandamide or oleamide increases REM sleep in rats. | 2010 | Pharmacol. Biochem. Behav. | pmid:20056119 |
| Rawls SM et al. | Role of TRPV1 and cannabinoid CB1 receptors in AM 404-evoked hypothermia in rats. | 2006 | Pharmacol. Biochem. Behav. | pmid:16647109 |
| Crawley JN et al. | Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. | 1993 | Pharmacol. Biochem. Behav. | pmid:7906042 |
| Wiley JL et al. | Evaluation of cannabimimetic discriminative stimulus effects of anandamide and methylated fluoroanandamide in rhesus monkeys. | 1997 | Pharmacol. Biochem. Behav. | pmid:9408225 |
| Wenger T et al. | The effects of prenatally administered endogenous cannabinoid on rat offspring. | 1997 | Pharmacol. Biochem. Behav. | pmid:9300616 |
| Reyes-Cabello C et al. | Effects of the anandamide uptake blocker AM404 on food intake depend on feeding status and route of administration. | 2012 | Pharmacol. Biochem. Behav. | pmid:22133635 |
| Tuboly G et al. | The antinociceptive interaction of anandamide and adenosine at the spinal level. | 2009 | Pharmacol. Biochem. Behav. | pmid:18760296 |
| Sulcova E et al. | Biphasic effects of anandamide. | 1998 | Pharmacol. Biochem. Behav. | pmid:9476980 |
| Sadhasivam S et al. | Novel associations between FAAH genetic variants and postoperative central opioid-related adverse effects. | 2015 | Pharmacogenomics J. | pmid:25558980 |
| Laine K et al. | Effects of topical anandamide-transport inhibitors, AM404 and olvanil, on intraocular pressure in normotensive rabbits. | 2001 | Pharm. Res. | pmid:11451037 |
| Pate DW et al. | Effects of topical alpha-substituted anandamides on intraocular pressure in normotensive rabbits. | 1997 | Pharm. Res. | pmid:9453062 |
| Krishtal O et al. | The agonists for nociceptors are ubiquitous, but the modulators are specific: P2X receptors in the sensory neurons are modulated by cannabinoids. | 2006 | Pflugers Arch. | pmid:16741755 |
| Kenessey I et al. | Revisiting CB1 receptor as drug target in human melanoma. | 2012 | Pathol. Oncol. Res. | pmid:22447182 |
| Farquhar-Smith WP et al. | Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors. | 2002 | Pain | pmid:12031775 |
| Horvath G et al. | The role of TRPV1 receptors in the antinociceptive effect of anandamide at spinal level. | 2008 | Pain | pmid:17533116 |
| Lichtman AH et al. | Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. | 2004 | Pain | pmid:15157693 |
| Guindon J et al. | Local interactions between anandamide, an endocannabinoid, and ibuprofen, a nonsteroidal anti-inflammatory drug, in acute and inflammatory pain. | 2006 | Pain | pmid:16480822 |
| Jaggar SI et al. | The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. | 1998 | Pain | pmid:9696473 |
| Butler RK et al. | Endocannabinoid-mediated enhancement of fear-conditioned analgesia in rats: opioid receptor dependency and molecular correlates. | 2008 | Pain | pmid:19004548 |
| Richardson JD et al. | Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. | 1998 | Pain | pmid:9539680 |